Immunocore Holdings plc - American Depositary Shares (IMCR)
29.43
+0.80 (2.79%)
NASDAQ · Last Trade: Apr 2nd, 6:55 PM EDT
Via Benzinga · March 20, 2025

Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.
Via Benzinga · December 13, 2024

Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.
Via MarketBeat · November 11, 2024

Via Benzinga · October 24, 2024

Via Benzinga · September 17, 2024

Via Benzinga · August 9, 2024

As sector rotation continues, it could be time for investors to consider these small-cap growth stocks that institutions love.
Via InvestorPlace · August 6, 2024

Via Benzinga · July 10, 2024

Via Benzinga · April 11, 2024

Via Benzinga · June 3, 2024

Via Benzinga · May 24, 2024

IMCR stock results show that Immunocore Hldgs missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 8, 2024

One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.
Via InvestorPlace · March 13, 2024

Via Benzinga · January 16, 2024